share_log

Actinium Announces Announced Five Abstracts Accepted For Presentation At 2024 SNMMI Annual Meeting

Benzinga ·  May 13 08:38

- Iomab-B and Actimab-A are the only targeted radiotherapies in for acute myeloid leukemia addressing different parts of the patient journey

- Improved survival demonstrated with both Iomab-B and Actimab-A in patients with high-risk acute myeloid leukemia including those with a TP53 mutation and prior venetoclax treatment

- Novel linker technology supports Actinium's Antibody Radiation Conjugate pipeline expansion in solid tumor indications

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment